Breakthrough in Colorectal Cancer Detection: Bridge Capture™ Promises More Sensitive and Scalable Liquid Biopsies
A recent announcement from Healthring, published on PR Newswire on July 14, 2025, has unveiled a significant advancement in the field of liquid biopsy for colorectal cancer (CRC). The company’s innovative Bridge Capture™ technology has demonstrated promising results in a pilot study, signaling a potential leap forward in the sensitivity and scalability of detecting this prevalent disease.
Liquid biopsy, a non-invasive diagnostic technique that analyzes biological material, such as blood or urine, for biomarkers indicative of cancer, holds immense promise for earlier and more accessible cancer screening and monitoring. However, challenges in sensitivity and the ability to scale these tests have been ongoing hurdles. Bridge Capture™ appears to address these limitations, offering a potentially more effective tool in the fight against colorectal cancer.
The pilot study, details of which are highlighted in the PR Newswire release, suggests that Bridge Capture™ significantly enhances the ability to detect circulating tumor DNA (ctDNA) – fragments of DNA shed by cancer cells into the bloodstream. Elevated levels of ctDNA are a key indicator of the presence and progression of cancer. By improving the capture and analysis of these minute genetic fragments, Bridge Capture™ aims to provide more accurate and reliable results, even in the early stages of colorectal cancer when tumors may be small and shedding minimal ctDNA.
The scalability of this technology is another crucial aspect of its potential impact. For a screening method to be widely adopted, it must be cost-effective and capable of being deployed on a large scale to reach a broad patient population. The pilot study’s success in demonstrating scalability is a positive indicator for the future widespread availability of this diagnostic approach.
Colorectal cancer remains a significant global health concern, and early detection is paramount for improving patient outcomes. Traditional screening methods, while effective, can sometimes be invasive or carry their own risks. The development of highly sensitive and scalable liquid biopsies, such as that offered by Bridge Capture™, could revolutionize how colorectal cancer is screened, diagnosed, and managed.
While this pilot study represents an important step, further research and larger clinical trials will be essential to fully validate the efficacy and utility of Bridge Capture™ across diverse patient populations and stages of colorectal cancer. Nevertheless, the initial findings are highly encouraging and suggest a brighter future for non-invasive cancer diagnostics. Healthring’s innovation with Bridge Capture™ offers a hopeful outlook for patients and healthcare providers alike, potentially paving the way for earlier intervention and ultimately, better survival rates for those affected by colorectal cancer.
Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot’ at 2025-07-14 07:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.